## Eva Muehlhofer

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10091503/publications.pdf

Version: 2024-02-01

1478505 1588992 8 703 6 citations h-index papers

g-index 8 8 8 742 docs citations times ranked citing authors all docs

8

#	Article	IF	CITATIONS
1	Rivaroxaban in Peripheral Artery Disease after Revascularization. New England Journal of Medicine, 2020, 382, 1994-2004.	27.0	566
2	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. Circulation, 2020, 142, 2219-2230.	1.6	58
3	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PADÂTrial. Journal of the American College of Cardiology, 2021, 78, 317-326.	2.8	30
4	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. Circulation, 2021, 144, 1831-1841.	1.6	19
5	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. European Journal of Preventive Cardiology, 2022, 29, e181-e189.	1.8	18
6	Sexâ€Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. Journal of the American Heart Association, 2022, 11, .	3.7	8
7	Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. Journal of Thrombosis and Haemostasis. 2022. 20. 1193-1205.	3.8	3
8	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation, 2022, 145, 1875-1877.	1.6	1